Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 232-238

  Marin, David ^a   Ibrahim, Amr R ^a   Lucas, Claire ^b   Gerrard, Gareth ^a   Wang, Lihui ^b   Szydlo, Richard M ^a   Clark, Richard E ^b   Apperley, Jane F ^a   Milojkovic, Dragana ^a   Bua, Marco ^a   Pavlu, Jiri ^a   Paliompeis, Christos ^a   Reid, Alistair ^a   Rezvani, Katayoun ^a   Goldman, John M ^a   Foroni, Letizia ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; DASATINIB; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862907694     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.6565     Document Type: Article

References (22)

1. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol 47:312-318, 2010
2. Marin D, Khorashad JS, Foroni L, et al: Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 145:373-375, 2009
3. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003 (Pubitemid 37211057)
4. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
5. Marin D, Kaeda J, Szydlo R, et al: Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19:507-512, 2005 (Pubitemid 40521152)
6. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006 (Pubitemid 43990609)
7. Foroni L, Wilson G, Gerrard G, et al: Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153: 179-190, 2011
8. Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444, 2008
9. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukaemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363, 2008
10. Milojkovic D, Nicholson E, Apperley JF, et al: Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95:224-231, 2010
11. Kantarjian HM, Dixon D, Keating MJ, et al: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441-1446, 1988 (Pubitemid 18076421)
12. Kaeda J, Chase A, Goldman JM: Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 107:64-75, 2002 (Pubitemid 34264170)
13. Kaeda J, O'Shea D, Szydlo RM, et al: Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: An attempt to define patients who may not require further therapy. Blood 107:4171-4176, 2006 (Pubitemid 43726829)
14. Craddock C, Szydlo RM, Klein JP, et al: Estimating leukemia-free survival after allografting for chronic myeloid leukemia: A new method that takes into account patients who relapse and are restored to complete remission. Blood 96:86-90, 2000 (Pubitemid 30456455)
15. Kleinbaum DG: Recurrent event survival analysis, in Kleinbaum DG, Klein M: Survival Analysis: A Self-Learning Text. New York, NY, Springer-Verlag, 2005
16. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
17. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1140-1154, 1988
18. Domenech JM, Navarro JB: Analisis de eventos recurrentes y de riesgos competitivos: Analisis de la supervivencia y modelo de riesgos proporcionales de Cox [in Spanish]. Barcelona, Spain, Signo, 2011
19. Hanfstein B, Müller MC, Erben P, et al: Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic myeloid leukemia: A follow-up analysis of the German CML Study IV. Presented at the 52nd ASH Annual Meeting and Exposition, Orlando, FL, December 4-7, 2010 (abstr 360)
20. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765, 2010
21. Wang L, Pearson K, Ferguson JE, et al: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120:990-999, 2003 (Pubitemid 36411558)
22. Ibrahim AR, Eliasson L, Apperley JF, et al: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733-3736, 2011